Guide
How GLP-1 Medication Works
How does GLP-1 medication work for weight loss?
GLP-1 medications work by mimicking a hormone the gut releases after eating. They slow the rate at which the stomach empties and act on appetite centres in the brain, so hunger falls and fullness lasts longer after a meal. The result is that people eat less without the constant effort that usually makes calorie restriction fail. They do not burn fat directly, the weight change comes from reduced intake.
The hormone these medicines copy
Glucagon-like peptide-1, or GLP-1, is a hormone released by cells in the small intestine when food arrives. It is an incretin, a signal from the gut to the rest of the body that eating has happened and the system should respond accordingly.
Naturally released GLP-1 breaks down within minutes. The medicines in this class are engineered to resist that breakdown, which is why a single injection can act across a whole week rather than a few minutes.
This distinction matters when people ask whether these medicines are "natural". The hormone is; the duration is not. The therapeutic effect comes precisely from sustaining a signal the body normally produces only in short bursts.
Three effects that combine
The appetite change people describe is not one mechanism but several acting together, which is why the experience differs from a stimulant appetite suppressant.
- Delayed gastric emptying
- Food remains in the stomach longer, so physical fullness persists for hours rather than minutes after a meal.
- Central appetite regulation
- Receptors in the hypothalamus and brainstem respond, reducing hunger signals and the intrusive food-related thoughts many people describe as "food noise".
- Glucose-dependent insulin release
- Insulin release is stimulated only when blood glucose is raised, which is why these medicines carry a low risk of hypoglycaemia when used alone.
Why some treatments act on two receptors
Tirzepatide, the active ingredient in Mounjaro, acts on a second incretin receptor as well: glucose-dependent insulinotropic polypeptide, or GIP. Semaglutide, in Wegovy, acts on GLP-1 alone.
The clinical significance of adding GIP was an open question until the treatments were compared directly. In the SURMOUNT-5 trial, published in the New England Journal of Medicine, tirzepatide produced a 20.2% mean weight reduction against 13.7% for semaglutide across 72 weeks.
That does not make one treatment correct for everyone. Tolerability, other medical conditions, existing medicines and individual response all bear on which is appropriate, and that judgement belongs to a prescriber.
What the mechanism means in practice
Because the effect works through appetite rather than metabolism, the medicine creates an opportunity rather than a result. Eating less becomes achievable; what is eaten still determines the outcome.
This explains two things people find surprising. First, protein and resistance exercise matter more on treatment than off it, because weight lost without them includes more muscle. Second, appetite generally returns when treatment stops, which is why a maintenance plan is part of the clinical picture rather than an afterthought.
It also explains the most common side effects. Slowing the stomach is the mechanism, so nausea, fullness and altered bowel habit are the mechanism showing itself, most noticeably in the days after a dose increase.
Common questions
Do GLP-1 medications burn fat?
No. GLP-1 medications do not burn fat or raise metabolic rate directly. They reduce appetite and slow gastric emptying, which lowers how much a person eats. The weight change follows from that reduced intake, which is why dietary and activity changes remain necessary.
What is "food noise" and why does it stop?
Food noise describes intrusive, recurring thoughts about eating. GLP-1 receptors in the brain are involved in appetite and reward signalling, and activating them reduces those signals. Many people report this as the most noticeable change, often before any weight change is measurable.
Why does nausea happen after a dose increase?
Nausea is the medicine's primary mechanism becoming noticeable. Delayed gastric emptying is how these treatments work, and each dose increase intensifies that effect before the body adapts. This is why doses are raised gradually, with at least four weeks between increases.
Is GLP-1 medication a lifelong treatment?
Not necessarily, but appetite typically returns to its previous level once treatment stops, and weight regain is common without a structured maintenance plan. Duration is a clinical decision made with your prescriber, based on your response, tolerability and wider health.
Sources
- Tirzepatide for managing overweight and obesity (TA1026) · NICE
- Obesity, treatment · NHS
- Mounjaro, Summary of Product Characteristics · electronic medicines compendium
- SURMOUNT-5: tirzepatide versus semaglutide · American College of Cardiology
Awaiting sign-off by a named clinician.
Last updated